ReviewRadiation oncology (London, England)2016
Target delineation and optimal radiosurgical dose for pituitary tumors.
Review in Radiation oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Radiosurgery in recurrent and persistent Cushing's Disease: a Systematic Review and Meta-Analysis.Neurosurgical review · 2026Pooled it
- Stereotactic radiosurgery for acromegaly: an international systematic review and meta-analysis of clinical outcomes.Journal of neuro-oncology · 2020Pooled it
- Pooled it
- A pilot study of [Clinical and translational radiation oncology · 2026Article
- Radiotherapeutic Strategies and Advances in the Management of Pituitary Adenomas.Neuroendocrinology · 2026Review
- Potentially radiation-induced late toxicity after irradiation of pituitary adenoma, a retrospective dosimetric study.Radiation oncology (London, England) · 2025Article
- Rapid Endocrine Remission After ZAP-X Gyroscopic Radiosurgery for Cushing's Disease: A Case Report.Cureus · 2025Article
- Article
- Protons or Photons in Pituitary Neuroendocrine Tumors-That Is Not the Question.International journal of particle therapy · 2025Article
- Hydrogel-based nanoparticles: revolutionizing brain tumor treatment and paving the way for future innovations.European journal of medical research · 2025Review
- An overview of hypopituitarism's causes.Frontiers in endocrinology · 2025Review
- Article
- Fractionated robotic radiosurgery for unfavorable nonfunctioning pituitary macroadenoma: 5-year outcomes from a single institution protocol.Frontiers in oncology · 2025Article
- Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.Neuro-oncology practice · 2024Review
- Refractory lactotroph adenomas.Pituitary · 2023Review
- The Party Wall: Redefining the Indications of Transcranial Approaches for Giant Pituitary Adenomas in Endoscopic Era.Cancers · 2023Review
- Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors.Frontiers in endocrinology · 2023Review
- Evolution in endoscopic endonasal approach for the management of hypothalamic-pituitary region metastasis: A single-institution experience.Frontiers in oncology · 2022Article
- The new SRS/FSRT technique HyperArc for benign brain lesions: a dosimetric analysis.Scientific reports · 2021Article
- Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma.Journal of neurological surgery. Part B, Skull base · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic radiosurgery (SRS) delivered as either single-fraction or multi-fraction SRS (2-5 fractions) is frequently employed in patients with residual or recurrent pituitary adenoma. The most common delivery systems used for SRS include the cobalt-60 system Gamma Knife, the CyberKnife (CK) robotic radiosurgery system, or a modified conventional radiotherapy machine (linear accelerator, LINAC). Tumor control and normalization of hormone hypersecretion have been reported in 75-100 % and 25-80 % of patients, respectively. Hypopituitarism is the most commonly reported late complication of radiation treatment, whereas other toxicities occur less frequently. We have provided an overview of the recent available literature on SRS in patients with a pituitary adenoma. Critical aspects of pituitary irradiation, including target delineation and doses to organs at risk, optimal radiation dose, as well as the long-term efficacy and toxicity of SRS for either nonfunctioning or secreting pituitary adenomas are discussed. Single-fraction SRS represents an effective treatment for patients with a pituitary adenoma; however, caution should be used for lesions > 2.5-3 cm in size and/or involving the anterior optic pathway. Future studies will be necessary to optimize target doses and critical organ dose constrains in order to reduce the long-term toxicity of treatments while maintaining high efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.